- Report
- October 2022
- 177 Pages
From €2022EUR$2,100USD£1,739GBP
€2889EUR$3,000USD£2,485GBP
- Report
- October 2022
- 174 Pages
North America
From €2022EUR$2,100USD£1,739GBP
€2889EUR$3,000USD£2,485GBP
- Report
- October 2022
- 181 Pages
Middle East, Africa
From €2022EUR$2,100USD£1,739GBP
€2889EUR$3,000USD£2,485GBP
- Report
- October 2022
- 202 Pages
Europe
From €2022EUR$2,100USD£1,739GBP
€2889EUR$3,000USD£2,485GBP
- Report
- October 2022
- 205 Pages
Asia Pacific
From €2022EUR$2,100USD£1,739GBP
€2889EUR$3,000USD£2,485GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 90 Pages
South Korea
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
India
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 90 Pages
France
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
Russia
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
Germany
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
Canada
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
Italy
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 70 Pages
Germany
From €4574EUR$4,750USD£3,934GBP
Humulin is a brand of insulin used to treat endocrine and metabolic disorders. It is a recombinant human insulin, produced by genetically engineered bacteria, and is used to treat diabetes mellitus. It is available in several forms, including short-acting, intermediate-acting, and long-acting. Humulin is used to control blood sugar levels in people with type 1 and type 2 diabetes. It is also used to treat other endocrine and metabolic disorders, such as hyperglycemia, hypoglycemia, and polycystic ovary syndrome.
Humulin is a widely used insulin, and is available in many countries around the world. It is available in both generic and branded forms, and is available in both injectable and oral forms. It is also available in combination with other medications, such as metformin and glipizide.
The Humulin market is highly competitive, with many companies offering their own versions of the drug. Some of the major companies in the market include Eli Lilly, Novo Nordisk, Sanofi, Merck, and Pfizer. Show Less Read more